Keli Walbert currently serves on the Board of Directors of Spruce Biosciences and previously served on the Board of Apellis Pharmaceuticals prior to its acquisition by Biogen. She brings more than 20 years of commercial leadership experience in biopharmaceuticals, spanning sales and marketing, market access, patient services, advocacy, digital and analytics, with deep therapeutic experience across immunology, rheumatology, dermatology, gastroenterology, ophthalmology, nephrology, neurology and metabolic disease, and particular strength in rare disease commercialization. She most recently served as Executive Vice President, U.S. Commercial at Horizon Therapeutics, where she oversaw commercial strategy and organizational development across more than 10 marketed brands in nephrology, ophthalmology and rare disease, including the launch of TEPEZZA® for thyroid eye disease. Earlier in her career, she held leadership roles at AbbVie, the American Medical Association, Abbott and United Healthcare, and over the course of her career led the commercial launches of HUMIRA® and DUOPA® as well. Ms. Walbert has been recognized with the Healthcare Businesswomen's Association's Luminary Award and an MM+M Women of Distinction Award. She earned her master's degree from Northwestern University and her bachelor's degree from the University of Louisville.

‍